- Dec 21, 2013
NCT01863550: Phase 3 - Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in NDMM
ENDURANCE TRIAL - ECOG-E1A11 (the ENDURANCE trial; E1A11) KRd VRd Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in...
180
- Dec 20, 2013
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory MM
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma The phase 1 primary...
123
- Dec 19, 2013
NCT01985126: Phase 2 - Dara in MM who had 3 prior lines inc. PI, Imid - or db. ref. MMY2002 (SIRIUS)
MMY2002 (SIRIUS) Study An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior...
285
- Dec 19, 2013
NCT01998971: Phase 1 - JNJ-54767414 (HuMax CD38) (Anti-CD38 Mono. Ab. ) in Myeloma EQUULEUS; MMY1001
Phase 1 b EQUULEUS study EQUULEUS; MMY1001 Study A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With...
678
- Dec 15, 2013
NCT01816971: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone Before and After ASCT NDMM
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple...
140
- Dec 14, 2013
NCT01980589: Phase 1b: Study of Carfilzomib, Cyclophosphamide and Dexamethasone in NDMM CHAMPION 2
CHAMPION 2 NCT01980589: Phase 1: A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly...
68